A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)
Clinical trial NCT05585645 · COMPLETED
Trial details
- NCT number
- NCT05585645
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-08
- Primary completion
- 2022-11-23
- Enrollment
- 214
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.